Search Results - "Gimenez‐Sanders, Mary Ann"

Risk stratification of ER‐positive breast cancer patients: A multi‐institutional validation and outcome study of the Rochester Modified Magee algorithm (RoMMa) and prediction of an Oncotype DX® recurrence score <26 by Turner, Bradley M., Gimenez‐Sanders, Mary Ann, Soukiazian, Armen, Breaux, Andrea C., Skinner, Kristin, Shayne, Michelle, Soukiazian, Nyrie, Ling, Marilyn, Hicks, David G.

“…The skyrocketing cost of health‐care demands that we question when to use multigene assay testing in the planning of treatment for breast cancer patients. A…”
Get full text

Abstract P4-06-07: Clinical risk-assessment, risk-stratification, and outcomes of ER positive, HER2 negative breast cancer patients using the Rochester modified Magee algorithm (RoMMA) by Numbere, Numbereye, Moisini, Ioana, Dhakal, Ajay, Skinner, Kristin, Shayne, Michelle, Sanders, Mary Ann Gimenez, Zhang, Huina, Hicks, David, Turner, Bradley M

“…INTRODUCTION: In 2013, Klein and Dabbs et al. published three linear regression equations (the new Magee equations) using different combinations of standard…”
Get full text

Abstract PS6-24: Are we missing something? Increased recurrence rates in patients with an oncotype DX score < 26 and a modified magee score > 18: A multi-institutional study by Turner, Bradley M, Gimenez-Sanders, Mary Ann, Moisini, Ioana, Zhang, Huina, Wang, Xi, Schiffhauer, Linda, Katerji, Hani, Skinner, Kristin, Gooch, Jessica, Shayne, Michelle, Ling, Marilyn, Falkson, Carla, Hicks, David

“…INTRODUCTION: Oncotype DX® (ODX) is a multigene assay estimating risk of distant recurrence and chemotherapy benefit in estrogen receptor (ER) positive breast…”
Get full text

Abstract PS6-18: Are we missing something? Ki-67 evaluation is important in African American women with an oncotype DX score< 26: A multi-institutional study by Turner, Bradley M, Gimenez-Sanders, Mary Ann, Zhang, Huina, Moisini, Ioana, Wang, Xi, Schiffhauer, Linda, Katerji, Hani, Skinner, Kristin, Gooch, Jessica, Shayne, Michelle, Ling, Marilyn, Falkson, Carla, Hicks, David

“…INTRODUCTION: The literature suggests that there is no difference in the Oncotype DX® (ODX) recurrence score between African American (AA) women and Caucasian…”
Get full text